Member Info for SocialistB

@JustHereForHemo

"Nothing has changed, arguably the only difference is todays drop has given Vlad even less options but to take what the VC is offering, so be it, we might give away a higher % of HG-CT-1, needs must!"

One alternative could be another Peterhouse special.

Much as I dislike them, if it turns out to be a better deal, because the VCs are to greedy, then I hope they chose the lesser of the 2 evils.

I am confident the BODwill be able to raise funds, they have proven themselves again and again.

(Just not at a favourable price point, but you gotta take what the market offers, if it's needed)

I ekko that to some degree.

There is a lot of uncertainty going on in the market at the moment, so question is if there is any appetite to make investment these next few weeks.

Maybe best to hold back any good news for a while.

But I am not to concerned about a tariff being imposed on our product.

If the UK government was to due that in a retaliatory move, they would just increase the expenses for the NHS.

Amove akin to shooting yourself in the foot.

Back to funding, dare I say it:

We might need another Peterhouse special if the market does not play ball and are interested in making investments in the current clima.

Although not happy with that, I'd accept it to keep the company afloat untill we get undeniable results that no major can allow themselves to ignore.

@HereforHemo

You have stayted that you have had some communication with Mr Sandler and yesterday you said among other things the following :

"There's two options, either he gets a loan or he engages with a VC and sells a percentage of HG-CT-1 on a phased drawdown for an increasing percentage that he either takes or doesn't, with an opinion to buy back any percentage given at a later date."

Regarding the latter option, I like that one in particular, has Mr Sandler been saying that's the option he likes the most and are aiming for?

Or is it a recepie that you have come up with( and a very good one, I might add)

@ Philthehopeful

You are absolutely right that the potential upside from here is enormous if Hemogenyx gets further funding sorted on palatable conditions for the market.

The problem is not that they have not managed to get funds, they have proven again and again that they are capable to do so.

The problem is that either the amount or the way it has been done has not been accepted kindly by the market.

Hemogenyx has now shown safety and efficacy with HG-CT-1, and the share is around the lowest level it has been, which is astonishing and a fantastic buying opportunity and entry point for first timers:-)

It clearly shows the old adage about the market knowing best, does not always apply.

And in my opinion Hemogenyx is such a case.

Because of course we are going to get further funds, the question is just at what cost.

If further funds can be achieved without issuing to many extra shares, then if you accept HereforHemo's suggestion about a buyout for 1 Billion dollars then that amount to slightly less then 250 dollars a share.

I hope with every fibre in my body that no one will accept such a paltry offer for the whole company, it would be akin to selling a gold calf for peanuts.

Paying no attention to the true value of CBR, and so far all indicators point towards it will do as it says on the tin.

HG-CT-1 was tested in lab and on mice and have now been shown to work in a human.

I hope and believe and want with every fiber in my body that to also be the case when it comes to CBR, (and CDX as well, I guess)

So if people do believe that funds will be secured, that Hemogenyx has products worth in excess of 1 Billion dollars, then right now is a fantastic entry level.

I envy those who can buy for the first time in Hemo, at this stage and at this price.

I wouldn't gamble and wait, but neither would I go all in.

@MrIndia

You stated the following:

"We now have a new option from Haywain and his major contacts. Hemo is getting interest from Saudi and other hospitals"

I have missed this completely, can you please direct me to the thread where I can find the information.

Thanks in advance and have a nice weekend.

Hemogenyx got funds.

This year they have managed to raise capital a couple of times despite not being in a position of strength.

And that clearly shows at the price and terms they have raised the sums at.

But they have managed and that is the key issue.

They have proven themselves to be capable.

And they have proven efficacy in HG-CT-1.

I expect they are now collaborating with Kure.ai on reducing the manufacturing time.

And on CBR and CDX in a cost effective way.

My hope is that if they sell a portion of HG-CT-1 then it will be as little as 10 percent on a loan basis with the right to convert it to 20 percent if they chose not to repay it within 2 years.

Just a suggestion for a potential ideal outcome.

Great news today.

Efficacy has been proven in a human being for the first time, with HG-CT-1.

And that is on the low starting dose.

Which was well tolerated.

I expect that the efficacy will improve as the dose increases.

There will be a point where we will be informed that there were side affects to the dose administered.

In my view, that is the point with phase 1, find the maximum dose.

But boy, is it nice to hear that the treatment shows efficacy at the lowest dose to be administered.

We know the treatment worked on mice and eradicated cancer, now there is every good reason to believe it will also achieve it in humans.

It has shown it works.

Onwards and upwards

Https://www.msn.com/en-gb/health/medical/a-new-pandemic-is-expected-and-the-uk-still-isn-t-prepared/ar-AA1Btwka?ocid=msedgdhp&pc=U531&cvid=dc31662a15f94310bc879ae347139df5&ei=45

Interesting article mentioning likely candidates like Ebola, Zika, Mpox and Disease X

I wonder if there is a company that already has something viable that works against those candidates.

Oh, wait, Hemogenyx does.

If the 28 days has not already passed, then it will soon.

Will we possibly hear something this afternoon after they have woken up on the East coast?

I doubt it (but it would be a nice surprise)

Hopefully we will hear something by Wednesday next week, that will give them a few days to analyse the instant feedback they are getting from the monitoring equipment.

But maybe I am to optimistic, then again 4 days ago we were told that they were about to select the second Patient, and that it was indicative of the trials progression.

The optimist in me says that means that the feedback from the immediate feedback monitoring systems are good.

What I do not know is if the monitoring system with immediate feedback only monitors the Patient wellbeing or if it also monitors the cancer cell status?

Haywain, do you have any idea about this, is there a monitoring system out there with instant feedback on number of cancer cells in the blood?

Claiming funds sorted may be a bit over the top.

But it makes for a good headline.

Now it is more difficult for the nay sayers to argue HEMO is about to run on fumes before we get the critical info from the first couple of patients.

It is also difficult for them to speculate or claim that a fund raise will come after good news being released, because the headroom is now severely shrunk, close to next to nothing.

But it is in the same breath we have to acknowledge that HEMO is going to need further funds.

However that is going to be achieved, it will cost us shareholders in one way or another.

Either we will lose a product candidate or a percentage of one.

I still question why the raise last week had to be done at such a huge discount and I hope we will get an answer some way down the line.

I secretly hope that there has been a bigger masterplan behind this that shows the detrimental consequences of naked shorting.

If that is the case, then now there is the evidence, so if the plan is to take the culprit to task afterwards and hopefully reform the system, then I personally it happy with what the task have cost me by adding 10 percent extra shares.

Anyway, great with good news today.

Upwards and onwards.

@MrsIndia.

Very valid questions you are raising, and I am sure that the LTHs that participated in the CLN would like some answers as do we all.

I do not have any inside knowledge and are the first to acknowledge that the following attempt for an explanation might not be anything more then a desperate attempt to cling on to straws.

If the goal of HEMO was to raise over 1 million, then they have achieved it.

And they might have achieved it with less dilution the way it have been done.

The LTHs wanted a discount and got it.

If that was to be the case to yesterday's 1.80, then the share price would fall even further.

By getting the higher price from LTHs, HEMO have achieved less dilution .

Since they are LTHs and have no intention of selling anytime soon, there is every chance that it will come good in the next 3-6 months.

They did not get the lowest entry point and that might sting a bit and I fully get if they feel they have been taken for a ride.

But I argue the science is still good , it should all pan out in the long run, HEMO own it 100 percent.

There is a lot to look forward to now we have sufficient funding for a couple og patients.

But there is a chock to overcome.

And again, an explanation would be nice.

@MrIndia

I am afraid the 28 days we all expected to be the milestone won't cut it.

Why on earth would the BOD raise a sum of money at this low price if they expected to be able to raise at a premium unless then 2 weeks time?

The conclusion that I have reached is that the BOD decided that 1 bird in the hand is better then 10 on the roof.

I am one of those who believed that prior to the first Patient being injected we would have seen a significant increase in the share price.

I have been proven utterly wrong .

Funds were needed, we new we needed to raise more, but we mistakenly assumed it would be at a higher price.

I have met Mr Sandler and Mr Redmond and believe them to be trustworthy and having the company's best interest at heart.

If I am not mistaken about that assumption, then it tells me a lot about the lack of offers out there or that the offers on the table at the moment are dreadfull.

I assume that they chose the best offer available.

I think every single investor has to be underwater and I feel for those who participated in the CLN, but could they have been told about this?

I am no expert, but had they been givne a hint about this planned operation then I think it would amount to insider information.

It's my understanding that they wanted to offer more money back then, if they still got them, they can now bay the cheapest shares ever.

Gotta look for the silverlining in a situation like this while we wait for the explanation.

I firmly believe we are owed one.

I was surprised by yesterday’s RNS announcement. Initially, I was hoping for a positive update regarding the medical trial, and it can be argued that there are some positive aspects to consider. The announcement did indicate that the trial is living up to expectations, which is encouraging news for all stakeholders involved.

Unfortunately, the primary focus of the RNS was on raising funds at a significant discount. This aspect has understandably caused a lot of upset among investors. It is well-known that the BOD does not favor raising capital at such low valuations, which raises an important question: why did they choose to proceed with this fundraising strategy?

Given the circumstances, I believe we are owed an explanation from the BOD regarding their decision-making process. Transparency in these matters is crucial for maintaining trust and confidence among investors.

Until we receive a satisfactory explanation, it’s essential to consider the context of this fundraising effort. Funds are needed to support 3-4 patients through the trial. What we received in yesterday’s announcement may not have been the most favorable offer in terms of pounds per share; however, it could be viewed as necessary for maintaining operational freedom and ensuring future profitability.

I think we may be in a situation where stronger entities prey on weaker ones. If this is indeed the case here, perhaps we should commend the BOD for successfully managing to raise over £1 million this year so far despite challenging conditions.

While this situation may seem disheartening in the short term, I remain hopeful that these efforts will pay off in the long run.

It is worthwhile to remember that yesterday there was nothing negative said about the clinical trial

Thanks for the update.

From a report, that makes ti even better in my book.

Don't search for it for my sake, I think what you posted encapsulated a lot useful information about what is going on in the pharma market regarding value and acquisition and what we are up against, as we are far from the only company with a clinical candidate.

I think that is something everyone sholud keep in mind, when claiming better PR is the salvation to our low share price.

@HereForHemo

Thank you for this informative post you uploaded the other day.

If, I am right in assuming that it is an answer to a question you asked an AI algorithm, may I ask you to please upload your question and which AI you used.

I find it interesting to experiment with different AI algorithms.

But back to the content of the post, it is no wonder that no one knows about HEMOGENYX if we are up against around 1699 other clinical blood related trials.

That's a lot for potential investors to get on top off.

But for us, invested in HEMOGENYX, it's reassuring to see that there is a

"remarkable 90% remission rate achieved by most of the approved CAR-T therapies."

We don't have to wait long now before we get an answer regarding the efficacy of HG-CT-1 in a human being and let's all hope it is as efficient as it was when it was tried on mice.

Because everyone in the knows seems to be impressed by those results.

@Saint68

Thanks for your thoughts.

I find them to be plausible and well founded.

But I am not as afraid at this stage for a hostile takeover, because the success of the candidates very much depends on the brains behind them.

And it would be silly of a company to risk upsetting them and go elsewhere and potentially become a competitor.

Or just not be able to crack the problems that lies ahead, we know that some of the issues the team has had to deal with has not been straight forward.

I am much more afraid of a friendly takeover, where the offer on the table is high enough for several investors to accept the offer.

But, I guess if the sum is high enough that could be considered to be a silverlining:-)

@HereForHemo

In my heart of hearts, I really do not want a takeover if HEMOGENYX.

But one thing is my wishful thinking and then what is going to happen.

But here is an argument why I think it is unlikely to be what is on the board at the moment at the BOD for both Prevail and HEMO.

I assume that Prevail is clued in tomore then we ordinary investors.

If the itnention of Prevail was to sell soon and basically just make a flip, then they would be sweeping up the shares on the open market at this ridiculous low price.

The absence of this behaviour indicates to me that they are going to invest further in the company.

But then again, I could be completely wrong about that:-)

@Saint68

We need money to progress our candidates.

Just at the top of my head:

Sell a candidate.

JV with a candidate

Investors at a premium to todays price, ( and the higher the better)

I am not afraid of Prevail getting a high percentage.

I am not aware of them having tried to buy a company before.

Even if they got 30 percent, which I think is the threshold where they have a legal obligation to offer to buy the company, then it does not mean that we have to sell.

But I think it's more likely they will bring other investors on board

I assume Prevail is waiting patiently in the corridor for positive news about HG-CT-1's safety and efficacy before committing more money then what has already been announced.

We have in the past seen that Prevail was willing to pay a premium of over 200 percent, in the region of 7 pence a share, which today, after consolidation, equals around the 28 quid territory.

HEMO are now further along the line, does that mean we will see an even higher Premium?

If it does, what would the price be?

I'll take a risk here and say 40 quid.

Insanely high compared to today price, I know.

But the less they pay, the less they lead the way, and we know they are looking for co-investors to join them regarding CBR.

The less they and others pay at this stage, the more shares will need to be issued in the future and thereby dilute their stake further.

Everybody should be able to see the advantages in only having to issue another Million shares, but get 40 million in the coffer.

If that was to happen, we might be able to hold onto HG-CT-1, which if successful has the potential to take a significant stake in a Billion dollars market.

Then imagine the company raising further funds based on a market cap 25 times their revenue, for further development of CBR.

Against all of this goes the common tendency of wanting to invest at a discount, but I think Prevail is aware of the potential downside of doing so in this case.

What is your guesstimate that Prevail will invest at, upon positive results?

@DanRey

I would like to add to your analysis that the BOD has actively sought to come out of the penny traders grip with the consolidation move and attract more institutions as investors.

In my view they are less likely to just jump on the wagon spontaneously and go for a ride, either for a short or long while.

There are a number of analytical decisions and calculations that has to be made, as the first rule if you wanna keep your job or be able to find a new one easily in that industry is to not LOOSE ANY MONEY.

At least, if you do you have to prove you took all reasonable precautions.

Right now, I think we are to high risk for those institutions.

Yes, every day that goes by without a negative RNS regarding HG-CT-1 is a victory.

But as I see it, that is just not enough evidence in the eyes of the institutions that this is a safe investment.

However, when HG-CT-1 is proven up, it becomes a different story.

Question is just how many of the institutions have already done some homework and made a decision as what goals should be reached before investing and their max entry price and their potential exit price.

Or will they first have to start all that work, when the positive results come through the door.

It will all have an impact on how quickly the share price start to move north.

Then there is of course the chance that some high risk individuals show up in the meantime, but for now they have not been seen.